Esters of acyl L-carnitine with gamma-hydroxybutyric acid, both as pharmacologically acceptable salts of formula (1) ##STR1## and as inner salts of formula (1') ##STR2## wherein X.sup.- is the anion of a pharmacologically acceptable acid and R is a straight or branched acyl group having from 2 to 5 carbon atoms, are used for producing pharmaceutical compositions effective for treating hepatopathies.
Dermatosis is treated by a method comprising topically applying an effective amount of an ester of L-carnitine or an acyl L-carnitine with a hydroxy carboxylic acid selected from the group consisting of .alpha.-hydroxybutyric acid, .alpha.-hydroxyisocaproic acid, .alpha.-hydroxyisovaleric acid, malic acid and tartronic acid, to a patient in need thereof.
Ester of L-carnitine and alkanoyl L-carnitines with glycolic acid and esters thereof are disclosed, which are formulated into topically applicable pharmaceutical compositions for the treatment of dermatoses.
The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.
